Login / Signup

Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo.

Abrar K ThabitMarguerite L MonogueDavid P Nicolau
Published in: Antimicrobial agents and chemotherapy (2016)
We assessed the pharmacokinetic profile of eravacycline, a novel antibiotic of the tetracycline class, and determined the dose in an immunocompetent murine thigh infection model that would provide free-drug exposure similar to that observed in humans after the administration of 1 mg/kg intravenously (i.v.) every 12 h (q12h). Eravacycline demonstrated a nonlinear protein-binding profile. The 2.5-mg/kg i.v. q12h dose in mice resulted in an area under the concentration-time curve for the free, unbound fraction of the drug of 1.64 mg · h/liter, which closely resembles the human exposure level.
Keyphrases
  • endothelial cells
  • adverse drug
  • adipose tissue
  • metabolic syndrome
  • protein protein
  • small molecule
  • induced pluripotent stem cells
  • high fat diet induced
  • soft tissue
  • pluripotent stem cells